Literature DB >> 15115645

Anticonvulsants in migraine.

William B Young1, Hua Chiang Siow, Stephen D Silberstein.   

Abstract

Migraine is a common, disabling disorder that often requires preventive treatment. The decision to treat migraine preventively generally is based on disability, problems with acute medicines, patient preference, risk of acute medication overuse, special circumstances, and concern that high migraine attack frequency may be a risk factor for chronic daily headache. Migraine and epilepsy are comorbid episodic central nervous system disorders that can have stereotyped symptoms with negative and positive phenomena. Controlled trials have demonstrated the efficacy of anticonvulsants in migraine prevention. Valproic acid, topiramate and, to a lesser extent, gabapentin, have demonstrated efficacy in randomized, placebo-controlled trials. Lamotrigine may be effective at controlling migraine aura, but has not demonstrated effectiveness at controlling migraine headache. Anticonvulsants are a useful option for the preventive treatment of migraine.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15115645     DOI: 10.1007/s11916-004-0059-z

Source DB:  PubMed          Journal:  Curr Pain Headache Rep        ISSN: 1534-3081


  35 in total

1.  Lamotrigine versus placebo in the prophylaxis of migraine with and without aura.

Authors:  T J Steiner; L J Findley; A W Yuen
Journal:  Cephalalgia       Date:  1997-04       Impact factor: 6.292

2.  A comparative trial of prindolol, clonidine and carbamazepine in the interval therapy of migraine.

Authors:  M Anthony; J W Lance; B Somerville
Journal:  Med J Aust       Date:  1972-06-24       Impact factor: 7.738

3.  Lamotrigine in the prophylactic treatment of migraine aura--a pilot study.

Authors:  C Lampl; A Buzath; D Klinger; K Neumann
Journal:  Cephalalgia       Date:  1999-01       Impact factor: 6.292

4.  Prevalence and burden of migraine in the United States: data from the American Migraine Study II.

Authors:  R B Lipton; W F Stewart; S Diamond; M L Diamond; M Reed
Journal:  Headache       Date:  2001 Jul-Aug       Impact factor: 5.887

5.  The growth of research on protein phosphorylation.

Authors:  E G Krebs
Journal:  Trends Biochem Sci       Date:  1994-11       Impact factor: 13.807

6.  Efficacy of gabapentin in migraine prophylaxis.

Authors:  N T Mathew; A Rapoport; J Saper; L Magnus; J Klapper; N Ramadan; B Stacey; S Tepper
Journal:  Headache       Date:  2001-02       Impact factor: 5.887

7.  Valproic acid hepatic fatalities: a retrospective review.

Authors:  F E Dreifuss; N Santilli; D H Langer; K P Sweeney; K A Moline; K B Menander
Journal:  Neurology       Date:  1987-03       Impact factor: 9.910

8.  Migraine prophylaxis with divalproex.

Authors:  N T Mathew; J R Saper; S D Silberstein; L Rankin; H G Markley; S Solomon; A M Rapoport; C J Silber; R L Deaton
Journal:  Arch Neurol       Date:  1995-03

9.  A randomized trial of divalproex sodium extended-release tablets in migraine prophylaxis.

Authors:  Frederick G Freitag; S D Collins; H A Carlson; J Goldstein; J Saper; S Silberstein; N Mathew; P K Winner; R Deaton; K Sommerville
Journal:  Neurology       Date:  2002-06-11       Impact factor: 9.910

10.  Neuroexcitatory plasma amino acids are elevated in migraine.

Authors:  M D Ferrari; J Odink; K D Bos; M J Malessy; G W Bruyn
Journal:  Neurology       Date:  1990-10       Impact factor: 9.910

View more
  6 in total

Review 1.  Practical considerations for the treatment of elderly patients with migraine.

Authors:  Paola Sarchielli; Maria Luisa Mancini; Paolo Calabresi
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

2.  Should magnesium be given to every migraineur? No.

Authors:  Arpad Pardutz; Laszlo Vecsei
Journal:  J Neural Transm (Vienna)       Date:  2012-03-18       Impact factor: 3.575

3.  A randomized trial of propranolol versus sodium valproate for the prophylaxis of migraine in pediatric patients.

Authors:  Elham Bidabadi; Mehryar Mashouf
Journal:  Paediatr Drugs       Date:  2010-08-01       Impact factor: 3.022

4.  Pediatric headache.

Authors:  Jack Gladstein
Journal:  Curr Treat Options Neurol       Date:  2006-11       Impact factor: 3.972

5.  Optimizing prophylactic treatment of migraine: Subtypes and patient matching.

Authors:  Michel Dib
Journal:  Ther Clin Risk Manag       Date:  2008-10       Impact factor: 2.423

6.  Prophylaxis of migraine.

Authors:  Ivan Garza; Jerry W Swanson
Journal:  Neuropsychiatr Dis Treat       Date:  2006-09       Impact factor: 2.570

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.